Mesenchymal Stem Cells for Perianal Crohn’s Disease

Cells. 2019;8(7):764 DOI 10.3390/cells8070764

 

Journal Homepage

Journal Title: Cells

ISSN: 2073-4409 (Online)

Publisher: MDPI AG

LCC Subject Category: Science: Biology (General)

Country of publisher: Switzerland

Language of fulltext: English

Full-text formats available: PDF, HTML

 

AUTHORS


Michele Carvello (Colon and Rectal Surgery Unit, Humanitas Clinical and Research Center, 20089 Rozzano, Italy)

Amy Lightner (Department of Colon and Rectal Surgery, Cleveland Clinic, Cleveland, OH 44195, USA)

Takayuki Yamamoto (Inflammatory Bowel Disease Centre, Yokkaichi Hazu Medical Centre, Yokkaichi, Mie 510-0016, Japan)

Paulo Gustavo Kotze (Colorectal Surgery Unit, Cajuru University Hospital, Catholic University of Paraná, Curitiba 80215-901, Brazil)

Antonino Spinelli (Colon and Rectal Surgery Unit, Humanitas Clinical and Research Center, 20089 Rozzano, Italy)

EDITORIAL INFORMATION

Blind peer review

Editorial Board

Instructions for authors

Time From Submission to Publication: 11 weeks

 

Abstract | Full Text

Perianal fistulizing Crohn’s disease (PFCD) is associated with significant morbidity and might negatively impact the quality of life of CD patients. In the last two decades, the management of PFCD has evolved in terms of the multidisciplinary approach involving gastroenterologists and colorectal surgeons. However, the highest fistula healing rates, even combining surgical and anti-TNF agents, reaches 50% of treated patients. More recently, the administration of mesenchymal stem cells (MSCs) have shown notable promising results in the treatment of PFCD. The aim of this review is to describe the rationale and the possible mechanism of action of MSC application for PFCD and the most recent results of randomized clinical trials. Furthermore, the unmet needs of the current administration process and the expected next steps to improve the outcomes will be addressed.